User profiles for Alistair Roddick
 | Alistair J RoddickOxford University Clinical Academic Graduate School Verified email at ndph.ox.ac.uk Cited by 2377 |
[HTML][HTML] Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled …
Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors
reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart …
reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart …
Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis
SL Zheng, AJ Roddick - Jama, 2019 - jamanetwork.com
… Author Contributions: Dr Zheng and Mr Roddick had full access to all of the data in the study
… Mr Roddick conducted and are responsible for the data analysis. Dr Zheng and Mr Roddick …
… Mr Roddick conducted and are responsible for the data analysis. Dr Zheng and Mr Roddick …
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality …
Importance The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2)
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) …
[HTML][HTML] Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Background Statin therapy is effective for the prevention of atherosclerotic cardiovascular
disease and is widely prescribed, but there are persisting concerns that statin therapy might …
disease and is widely prescribed, but there are persisting concerns that statin therapy might …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
…, E Spata, G Pessoa-Amorim, M Campbell, A Roddick… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …
[HTML][HTML] Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
N Staplin, AJ Roddick, J Emberson, C Reith… - …, 2021 - thelancet.com
Background The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors
across different patient groups have not been quantified. Methods We performed a meta-…
across different patient groups have not been quantified. Methods We performed a meta-…
[HTML][HTML] Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant …
…, C Harper, L Holland, K Wilson, AJ Roddick… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Previous meta-analyses of summary data from randomised controlled trials have
shown that statin therapy increases the risk of diabetes, but less is known about the size or …
shown that statin therapy increases the risk of diabetes, but less is known about the size or …
[HTML][HTML] Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
…, D Preiss, SYA Ng, AJ Roddick… - The Lancet Diabetes & …, 2024 - thelancet.com
Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the
primary composite outcome of kidney disease progression or cardiovascular death in patients …
primary composite outcome of kidney disease progression or cardiovascular death in patients …
Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of
its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in …
its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in …
Discontinuation and non-publication of clinical trials in cardiovascular medicine
Background Appropriate dissemination of clinical data is crucial for minimising bias. Despite
this, high rates of study discontinuation and non-publication have been reported among …
this, high rates of study discontinuation and non-publication have been reported among …
